Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 2394Neoplasms 1813Carcinoma, Non-Small-Cell Lung 1596Prostatic Neoplasms 1296Colorectal Neoplasms 1138Lung Neoplasms 981Neoplasm Metastasis 830Multiple Myeloma 791Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 661Melanoma 659Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 566Recurrence 562Brain Neoplasms 526Glioblastoma 512Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 464Lymphoma 453Uterine Cervical Neoplasms 449Carcinoma, Renal Cell 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 388Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 351

Interventions

Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer × 1 year × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡